The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
NCT03487913
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
DRUG:
Lixivaptan
Sponsor
Palladio Biosciences